News

Net profit of Strides Pharma Science rose 57.52% to Rs 156.91 crore in the quarter ended June 2026 as against Rs 99.61 crore during the previous quarter ended June 2025. Sales rose 13.01% to Rs 1265.41 crore in the quarter ended June 2026 as against Rs 1119.74 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales1265.411119.74 13 OPM %18.0619.48 - PBDT192.82179.30 8 PBT136.42130.41 5 NP156.9199.61 58 Powered by Capital Market - Live News

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Strides Pharma Science announced that the 35th Annual General Meeting(AGM) of the company will be held on 14 August 2026.

Net profit of Strides Pharma Science rose 54.45% to Rs 126.94 crore in the quarter ended March 2026 as against Rs 82.19 crore during the previous quarter ended March 2025. Sales rose 11.18% to Rs 1323.47 crore in the quarter ended March 2026 as against Rs 1190.39 crore during the previous quarter ended March 2025.For the full year,net profit declined 84.52% to Rs 556.19 crore in the year ended March 2026 as against Rs 3593.46 crore during the previous year ended March 2025. Sales rose 6.43% to Rs 4858.68 crore in the year ended March 2026 as against Rs 4565.34 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1323.471190.39 11 4858.684565.34 6 OPM %18.1118.30 -19.0417.58 - PBDT207.71182.66 14 897.93614.52 46 PBT154.46133.80 15 695.53422.26 65 NP126.9482.19 54 556.193593.46 -85 Powered by Capital Market - Live News

Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 18 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.